share_log

NKGen Biotech Publishes Phase 1 Interim Analysis Results of SNK02 Allogeneic NK Cell Therapy in Advanced Solid Tumors at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

NKGen Biotech Publishes Phase 1 Interim Analysis Results of SNK02 Allogeneic NK Cell Therapy in Advanced Solid Tumors at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

NKGen Biotech 在 2024 年美國臨床腫瘤學會 (ASCO) 年會上發佈了晚期實體瘤中 SNK02 異基因 NK 細胞療法的 1 期中期分析結果
GlobeNewswire ·  05/24 05:05

SNK02 has the potential to be a first-in-class cryopreserved allogeneic NK cell therapy for solid tumors that does not require lymphodepletion before administration, which may lead to better overall synergy in future combination regimens with immune checkpoint inhibitors.

SNK02 有可能成爲首創的針對實體瘤的冷凍保存異體 NK 細胞療法,這種療法在給藥前不需要淋巴消耗,這可能會改善未來與免疫檢查點抑制劑聯合療法的整體協同作用。

In this Phase 1 trial, the best objective response of stable disease was demonstrated in 100% of patients that completed 8 treatment cycles of SNK02.

在這項 1 期試驗中,在完成 8 個 SNK02 治療週期的患者中,100% 的患者證實了穩定疾病的最佳客觀反應。

SNK02 was well tolerated as a monotherapy and appears to have some clinical activity against pretreated solid tumors despite the lack of lymphodepletion.

SNK02 作爲單一療法具有良好的耐受性,儘管沒有淋巴消耗,但似乎對預先治療的實體瘤具有一定的臨床活性。

SANTA ANA, Calif., May  23, 2024  (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer ("NK") cell therapeutics, today announced an online publication, titled "Interim Analysis of a Phase I Study using Cryopreserved Non-genetically Modified Allogeneic Natural Killer Cells With Enhanced Cytotoxicity (SNK02) in Patients with Advanced Solid Tumors without Lymphodepletion" at the 2024 American Society of Clinical Oncology ("ASCO") Annual Meeting to be held virtually and at the McCormick Place Convention Center in Chicago, Illinois from May 31–June 4, 2024.

加利福尼亞州聖安娜,2024年5月23日(GLOBE NEWSWIRE)——專注於創新自體、異基因和CAR-NK自然殺傷(“NK”)細胞療法開發和商業化的臨床階段生物技術公司 NKGen Biotech, Inc.(納斯達克股票代碼:NKGN)(“NKGen” 或 “公司”)今天宣佈了一份在線出版物,名爲 “中期分析” 使用冷凍保存的具有增強細胞毒性(SNK02)的非基因改造異基因自然殺傷細胞(),用於 2024 年 “無淋巴消耗的晚期實體瘤患者” 的 I 期研究美國臨床腫瘤學會(“ASCO”)年會將於 2024 年 5 月 31 日至 6 月 4 日在伊利諾伊州芝加哥的味好美廣場會議中心以虛擬方式舉行。

This Phase 1 clinical trial is a multi-center, open-label study evaluating the safety and tolerability of SNK02 in participants with pathologically confirmed solid tumors refractory to standard of care therapy. The study drug, SNK02, is a first-in-kind, cryopreserved allogeneic non-genetically modified NK cell product with significant anti-tumor cytotoxicity and over 90% expression of CD16, NKG2D, NKp46, and DNAM-1, that can be consistently produced on a large commercial scale. SNK02 was administered as an intravenous infusion (IV), weekly for eight weeks in patients with advanced solid tumors. The starting dose was 6x109 SNK02 cells. We hypothesized that higher doses of SNK02 (to overcome autodigestion) could be delivered frequently without the need for lymphodepletion and that it might demonstrate activity against solid tumors that have failed multiple prior standard-of-care treatment options. The primary endpoint was safety based on adverse events (AEs), vitals, laboratory tests, and physical exams. Tolerability of SNK02 and maximum tolerated dose were also evaluated.

這項 1 期臨床試驗是一項多中心、開放標籤的研究,評估 SNK02 對經病理證實且不符合標準護理療法的實體瘤的參與者的安全性和耐受性。該研究藥物 SNK02 是同類首創、冷凍保存的非轉基因非轉基因 NK 細胞產物,具有顯著的抗腫瘤細胞毒性,CD16、NKG2D、nkp46 和 DNAM-1 的表達量超過 90%,可以在大規模商業規模上持續生產。對於晚期實體瘤患者,SNK02 以靜脈輸注(IV)的形式給藥,持續八週。起始劑量爲 6x109 個 SNK02 細胞。我們假設,無需淋巴消耗即可頻繁輸送更高劑量的 SNK02(以克服自身消化),並且它可能顯示出對先前多種標準護理治療方案失敗的實體瘤的活性。主要終點是基於不良事件 (AE)、生命體徵、實驗室測試和體格檢查的安全性。還評估了 SNK02 的耐受性和最大耐受劑量。

"Interim data from our Phase 1 clinical study utilizing our second NK cell therapy product, SNK02, demonstrated that the treatment was well-tolerated as a monotherapy in patients with solid tumors refractory to standard of care therapy," said Paul Y. Song, MD, Chairman and CEO of NKGen. "We are particularly excited because SNK02 has the potential to be a first-in-class cryopreserved allogeneic NK cell therapy for solid tumors that does not require lymphodepletion before administration, which may lead to better overall synergy in future combination regimens especially with immune checkpoint inhibitors where a robust T-cell response is needed. Using our proprietary allogeneic manufacturing and cryopreservation processes, we are capable of producing hundreds of thousands of potential doses of enhanced NK cell therapies from materials collected from a single donor. Thus, our potential to treat a significant number of cancer patients with SNK02 is remarkably high. We are pleased to see such promising Phase 1 trial results for both of our unique cell therapy candidates: autologous SNK01 for neurodegenerative disease and allogeneic SNK02 for cancer."

NKGen董事長兼首席執行官Paul Y. Song醫學博士表示:“我們使用我們的第二款NK細胞療法產品 SNK02 進行的1期臨床研究的中期數據表明,該療法作爲單一療法對標準護理療法難治的實體瘤患者具有良好的耐受性。”“我們特別興奮,因爲 SNK02 有可能成爲首創的針對實體瘤的冷凍保存同種異體 NK 細胞療法,這種療法在給藥前不需要淋巴消耗,這可能會在未來的聯合方案中帶來更好的整體協同作用,尤其是需要強大 T 細胞反應的免疫檢查點抑制劑。使用我們專有的同種異體制造和冷凍保存工藝,我們能夠利用從單個捐贈者那裏收集的材料生產數十萬種潛在劑量的增強型 NK 細胞療法。因此,我們用 SNK02 治療大量癌症患者的潛力非常高。我們很高興看到我們兩種獨特的候選細胞療法的1期試驗結果如此令人鼓舞:用於神經退行性疾病的自體 SNK01 和用於癌症的異基因 SNK02。”

For additional information on the SNK02 clinical trial, please visit  using the identifier NCT05990920.

有關 SNK02 臨床試驗的更多信息,請使用標識符 NCT05990920 訪問。

Highlights from the online publication include:

在線出版物的亮點包括:

  • Five patients with advanced refractory solid tumors were enrolled in the trial.

  • Patients had received an average of 4 lines of prior therapy.

  • Median age was 64 (range 44 – 71) and 3 were male.

  • The subtypes were 1 leiomyosarcoma, 1 angiosarcoma, 1 endometrial adenocarcinoma, 1 undifferentiated pleomorphic sarcoma, and 1 colorectal adenocarcinoma.

  • Four of five patients completed 8 cycles of SNK02. The best objective response of stable disease (tumor stopped growing) was demonstrated in 100% of patients that completed the 8 cycles.

  • Out of the 36 doses administered through Cycle 8, there were 17 Grade 1, 3 Grade 2, and 1 Grade 3 adverse events (AEs) related to investigational product (IP). The Grade 3 AE of increased fatigue resolved after 1 day with no intervention required.

  • There was 1 death on study, which was deemed unrelated to the IP.

  • Auto-antibodies appeared to develop around cycle 5 and appeared to correlate with AEs.

  • SNK02 was well tolerated as a monotherapy and appears to have some clinical activity against pretreated solid tumors despite the lack of lymphodepletion. SNK02 will continue to be studied as a monotherapy and in potential combination treatment regimens with monoclonal antibodies and immune checkpoint inhibitors.

  • 該試驗招收了五名晚期難治性實體瘤患者。

  • 患者先前平均接受了4線治療。

  • 中位年齡爲64歲(範圍在44-71歲之間),其中3人爲男性。

  • 亞型爲 1 種平滑肌肉瘤、1 種血管肉瘤、1 種子宮內膜腺癌、1 種未分化多形肉瘤和 1 種結直腸腺癌。

  • 五名患者中有四名完成了 SNK02 的 8 個週期。在完成8個週期的患者中,100%顯示了穩定疾病(腫瘤停止生長)的最佳客觀反應。

  • 在第8週期給藥的36劑中,有17種與研究產品(IP)相關的1級、3種2級和1種3級不良事件(AE)。3 級疲勞加劇症狀在 1 天后緩解,無需干預。

  • 研究中有1人死亡,被認爲與知識產權無關。

  • 自身抗體似乎在週期5前後形成,似乎與不良反應相關。

  • SNK02 作爲單一療法具有良好的耐受性,儘管沒有淋巴消耗,但似乎對預先治療的實體瘤具有一定的臨床活性。SNK02 將繼續作爲單一療法和潛在的單克隆抗體和免疫檢查點抑制劑聯合治療方案進行研究。

A copy of the ePublication will be available on the Scientific Publications page of the Company's website

電子出版物的副本將在公司網站的科學出版物頁面上公佈

About SNK02

關於 SNK02

SNK02 is a novel cell-based, donor-derived ex vivo expanded allogeneic natural killer ("NK") cell, immunotherapeutic drug candidate. NKGen Biotech, Inc. is developing SNK02 for the treatment of a broad range of cancers.

SNK02 是一種新型的基於細胞、由捐贈者衍生的體外擴增異基因自然殺傷(“NK”)細胞,是免疫治療候選藥物。NKGen Biotech, Inc. 正在開發 SNK02,用於治療各種癌症。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論